|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
delivers cytotoxic agent to cancer cells
HE R2 receptor blockade
microtubule disruption
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:trastuzumab
chemotherapy
|
|
gptkbp:clinical_trial
|
gptkb:EMILIA_trial
gptkb:KATHERINE_trial
gptkb:MARIANNE_trial
Phase III
adjuvant therapy
neoadjuvant therapy
T H3 RESA trial
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trastuzumab emtansine
|
|
gptkbp:indication
|
metastatic breast cancer
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_used_for
|
treatment of HE R2-positive breast cancer
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 4 days
|
|
gptkbp:provides_information_on
|
ASCO guidelines
ESMO guidelines
NCCN guidelines
|
|
gptkbp:research_areas
|
gptkb:Company
gptkb:drug
oncology
|
|
gptkbp:rounds
|
hepatic
|
|
gptkbp:side_effect
|
fatigue
nausea
liver toxicity
hypersensitivity
thrombocytopenia
neuropathy
infusion reactions
cardiotoxicity
|
|
gptkbp:social_structure
|
gptkb:monoclonal_antibody
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
HE R2 protein
|
|
gptkbp:traded_on
|
gptkb:Kadcyla
|
|
gptkbp:bfsParent
|
gptkb:Immuno_Gen
|
|
gptkbp:bfsLayer
|
5
|